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DOES PROPHYLACTIC ENDOSCOPIC SCLEROTHERAPY
PREVENT VARICEAL BLEEDING OR NOT? A QUESTION OF
EXPERIMENTAL DESIGN
Some circumstantial evidence is very strong,
as when you find a trout in the milk Thoreau
ABSTRACT
l/an Thiel, D. H., Dindzans, V. J., Schade, R. R., Rabinovitz, M. and Gavaler, J. S. (1993)
Prophylactic versus emer#ency sclerotherapy of lar#e esopha#eal varices prior to liver
transplantation. Di#estive Diseases and Sciences; 38 1505-1510
From January 1985 through July 1987, adult patients accepted for liver transplantation
with large esophageal varices were enrolled in a study evaluating the use ofprophylactic vs
emergency sclerotherapy. Six hundred forty-eight subjects received prophylactic sclero-
therapy, and 172 received emergent sclerotherapy. Esophageal stricture formation was
increased 12.9-fold (P < 0.001), esophageal perforation 6.4-fold (P < 0.005), and post-
sclerotherapy bleeding esophageal ulcers 3.7-fold (P< 0.001) in those receiving emerg-
ency sclerotherapy as opposed to prophylactic sclerotherapy. These differences were even
greater if the number of sclerotherapy sessions rather than the number of patients was
used as the denominator for the comparisons. In total, 19.6% ofemergency sclerotherapy
cases were associated with an untoward outcome of sclerotherapy; only 1.9% of cases
receiving prophylactic sclerotherapy experienced an untoward outcome (P < 0.001).
These data demonstrate that leinergency sclerotherapy is associated with a greater
prevalence of complications and support earlier studies that show that sclerotherapyHPB INTERNATIONAL 155
prevents variceai bleeding over the short term. The data also suggest that when applied to
patients with large varices awaiting orthotopic liver transplantation, it enhances the
chance of a patient surviving to be transplanted by preventing a variceal bleed and the
spiral of liver failure and death that frequently follows an episode of acute variceal
bleeding.
KEY WORDS: Sclerotherapy, portal hypertension, oesophageal varices
PAPER DISCUSSION
Van Thiel and associates report that prophylactic
endoscopic sclerotherapy (EST) in patients "with
advanced liver disease awaiting liver transplanta-
tion...reduces the number of bleeding episodes,
the frequency of emergency sclerotherapy sessions,
and, therefore, the complications of sclerotherapy...’’1.
This conclusion appears to be at variance with
most of the randomized clinical trials (RCTs) of
prophylactic EST published in peer reviewed journals,
which suggests that the incidence of hemorrhage
from esophageal varices (HEV) and death are either
unaffected2-6 or increased by prophylactic scler-
otherapy7,8.
Why this difference? In my opinion it represents
the difference between prospective, randomized
controlled trials and poorly controlled, contrived
comparisons. Both sets of observations are correct, but
the two groups of patients studied were very different.
Furthermore, in the transplant study of Van Thiel
et al. the "control" group is uncontolled, i.e., it is
not an appropriate control group. Indeed, the patients
who had prophylactic EST and those assigned to be
the control patients are disparate groups that are
vaguely defined, differently selected and, in fact, quite
dissimilar.
When prophylactic EST has been evaluated in
properly performed RCTs the untreated control
groups have been shown to have no more fatalities and
hemorrhages than those who received prophylactic
EST-8. In only two such studies has EST induced
a significant reduction in risk9,t o, and these two inves-
tigations are the first two RCTs on prophylactic EST
ever performed. They share a common flaw. In both
studies many of the control patients who died ofHEV
did so after the second, third or some subsequent
hemorrhage. In these trials the untreated control sub-
jects were permitted to run the risks ofrepeated hemor-
rhages without the right of rescue by portal-systemic
anastomosis or any other alternative form of therapy.
Thus, the flaw in these studies is that they were design-
ed before Human Investigation Committees required
that "escape clauses" be incorporated into such investi-
gations to protect patients against the failure of
"control" therapy. They can be considered inves-
tigational "dinosaurs", vestiges of an earlier age of
clinical research in which the primary hypotheses is
relentlessly pursued unto death, if necessary. Such
studies appear to be more effective in showing the
hazards ofan old therapy than the advantages ofa new
one. Furthermore, as shown in recent analyses of the
quality of RCTst, these two early studies were
awarded low quality scores. Such phenomena repre-
sent some of the disadvantages of being a pioneer and
not a follower.
How did the study ofVan Thiel et al. differ in design
from the later investigations that showed that prophy-
lactic EST seems to increase the risks of HEV and
death? In the "negative" RCTs2-8 the patients were
randomly selected to have prophylactic EST or to be
control subjects who were to be treated as identically as
possible to the EST groups, including in one of these
studies, sham EST injections of sclerosant into the
esophageal lumen8.
In the investigation of Van Thiel et al. two groups
of preselected patients, all ofwhom had been admitted
to Presbyterian University Hospital in Pittsburgh,
where they had undergone formal evaluation for liver
transplantation between January 1985 and July 1987,
were studied. Those who had been evaluated on the
medical service had prophylactic EST "...when in-
dicated by the size of their varices, as the attending
surgeon was an advocate ofEST, while those admitted
to the surgical service received EST only under emerg-
ency conditions associated with active variceal hemor-
rhage, as the attending surgeon was skeptical of the
management of potential transplant recipients by
EST...No difference, other than the use ofprophylactic
EST on the medical service, but not the surgical service
existed..." That seems to be an unambiguous statement,
but is it? "Patients were admitted to either service based
solely upon the basis of the referral" (editorialist’s
italics). Now that is a very ambiguous statement that156 HPB INTERNATIONAL
could cover a multitude ofbiases.We learn later that "a
majority of the patients with hepatocellular carcinoma
and cholangiolar carcinoma were admitted to the sur-
gical service, while more patients with advanced non-
malignant, chronic liver disease were admitted to the
medical service". The key phrase seems to be".., solely
on the basis of referral". Therein lies the tale. Did one
person make all the referrals to a single surgeon on
each service? Did he or she work every hour of every
day for two and one-halfyears? Transplant surgeons in
Pittsburgh are a dedicated lot, but even Tom Starzl
isn’t that dedicated. Were the referrals always ac-
cepted exactly as referred, and what factors are
involved in making such referrals and in their ac-
ceptance? Certainly, such factors must determine
why two-thirds of the patients accepted for possible
liver transplantation were on the surgical service and
only one-third on the medical service. Somehow more
than .half the patients with large varices (686) were
on the medical service, compared to only 628 on the
surgical service. Furthermore, the odds of dying
of HEV on the surgical service was 6.1 times greater
than on the medical service. It seems unlikely that
prophylactic EST was performed in equal numbers of
medical and surgical patients. Somehow, other factors
than the spontaneous occurrences of HEV, which ex-
cluded patients from prophylactic EST, must have
been operative.
Thus, the authors’ conclusions cannot be accepted as
presented because the groups compared are not com-
parable.
Somehow, the assignment of the two groups of
patients to the medical and surgical services reminds
me of a conversation between two pediatric patients.
The veteran patient, who awoke one morning to find
a new patient lying in the next bed asked, "Are you
medical or surgical?"
The newcomer responded, "How can you tell?"
The first patient replied, "Medical patients come
to the hospital sick and get well; surgical patients
are admitted healthy and get sick." Perhaps, the
study of Van Thiel is just another example of that
syndrome.
Finally, I believe that ifaRCT evaluatingEST is ever
performed in unselected patients awaiting transplan-
tion, it will show that the patients who require emerg-
ency EST will have more complications of EST than
those who do not, as was found by Van Thiel et al. and
as would be expected. I predict, however, that those
who had prophylactic EST will probably also have
more endoscopic complications and, probably, a high-
er mortality rate than those who did not have prophy-
lactic EST. It is clear that I have strong faith in real
RCTs!
ADDENDUM
Prior to submitting this manuscript to HPB Surgery
I sent a copy of it to Dr. Van Thiel and requested his
criticisms and suggestions. He responded as follows:
Dear Dr. Conn,
I think you missed several critical points. These are:
1. Unlike all other studies comparing prophylactic
sclerotherapy vs. no treatment, our study and its
conclusions are limited to patients with advanced
disease referred to and waiting for a liver transplant.
Survival was to time of transplant not until death.
We simply say that in this high risk group, elective
prophylactic therapy is safer than emergent therapy.
Moreover, it en-ables more patients to remain ac-
tive transplant candidates and ultimately to survive
to be transplanted.
2. The fact that the patients who were sicker were on
the medical service and more tumor patients were on
the surgical service does mean the groups were
different but would not have been expected to bias the
results in favor ofthose on the transplant service (less
time to transplant fortumor patients; less severe hepatic
disease; fewer cases actually receiving the potentially
dangerous sclerotherapy). This, however, did not occur.
With these two exceptions and the recognition that
doing studies of this sort in a transplant population is
difficult at best. I have to agree with your other com-
ments. Nonetheless, our study has value and one can
learn from an experience that is not randomized. Most
of us learn, most of what we learn about life, let alone
medicine, in an uncontrolled manner. Yet we learn.
David van Thiel, M. D.
I agree that one can learn from nonrandomized
observations, but not when the questions are begged
and the results are loosely interpreted.
Harold O. Conn, M. D.
Professor of Medicine, Emeritus
Yale University School of Medicine
Department of Veterans Affairs Medical Center,
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